Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer

J Thorac Oncol. 2017 Jul;12(7):e85-e88. doi: 10.1016/j.jtho.2017.02.020. Epub 2017 Mar 6.

Authors

Emily R York¹, Marileila Varella-Garcia¹, Tami J Bang², Dara L Aisner³, D Ross Camidge⁴

Affiliations

¹ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
² Department of Radiology, University of Colorado School of Medicine, Aurora, Colorado.
³ Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
⁴ Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: ross.camidge@ucdenver.edu.

PMID: 28274743
DOI: 10.1016/j.jtho.2017.02.020

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Acrylamides
Adult
Aniline Compounds
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Crizotinib / pharmacology
Crizotinib / therapeutic use*
ErbB Receptors / genetics
ErbB Receptors / metabolism
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Piperazines / pharmacology
Piperazines / therapeutic use*

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
Piperazines
osimertinib
Crizotinib
EGFR protein, human
ErbB Receptors

Grants and funding

P50 CA058187/CA/NCI NIH HHS/United States